HOLOGIC INC Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 33 rows in 2022. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2022-11-15: Reporting owner Thornal Kevin R; Form 4; Security Non-qualified Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2022-11-14: Reporting owner Griffin John M.; Form 4; Security Non-qualified Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2022-11-11: Reporting owner MACMILLAN STEPHEN P; Form 4; Security Non-qualified Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2022-11-07: Reporting owner Thornal Kevin R; Form 4; Security Non-qualified Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2022-11-15 | Thornal Kevin R Officer (Group Pres, Global Diagnostics) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −12,490 0 owned after | $40.85 exercise price | 2022-11-17 | |
| 2022-11-14 | Griffin John M. Officer (General Counsel) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −26,902 0 owned after | $40.85 exercise price | 2022-11-16 | |
| 2022-11-11 | MACMILLAN STEPHEN P Director, Officer (Chairman, President and CEO) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −95,422 95,422 owned after | $26.21 exercise price | 2022-11-14 | |
| 2022-11-07 | Thornal Kevin R Officer (Group Pres, Global Diagnostics) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +19,327 19,327 owned after | $74.35 exercise price | 2022-11-09 | |
| 2022-11-07 | MACMILLAN STEPHEN P Director, Officer (Chairman, President and CEO) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +106,300 106,300 owned after | $74.35 exercise price | 2022-11-09 | |
| 2022-11-07 | Oberton Karleen Marie Officer (Chief Financial Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +21,743 21,743 owned after | $74.35 exercise price | 2022-11-09 | |
| 2022-11-07 | Verstreken Jan Officer (Group President, International) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +19,327 19,327 owned after | $74.35 exercise price | 2022-11-09 | |
| 2022-11-07 | Mitchell Essex D Officer (Div. President, GYN Surgical) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,596 11,596 owned after | $74.35 exercise price | 2022-11-09 | |
| 2022-11-07 | Hellmann Elisabeth A Officer (SVP, Human Resources) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,764 6,764 owned after | $74.35 exercise price | 2022-11-09 | |
| 2022-11-07 | Griffin John M. Officer (General Counsel) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,394 17,394 owned after | $74.35 exercise price | 2022-11-09 | |
| 2022-11-07 | COHN BENJAMIN JORDAN Officer (Principal Accounting Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,382 3,382 owned after | $74.35 exercise price | 2022-11-09 | |
| 2022-11-07 | Anderson Erik S Officer (Div. Pres., Breast & Skeletal) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,663 9,663 owned after | $74.35 exercise price | 2022-11-09 | |
| 2022-11-01 | Oberton Karleen Marie Officer (Chief Financial Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,156 0 owned after | $39.96 exercise price | 2022-11-03 | |
| 2022-11-01 | Oberton Karleen Marie Officer (Chief Financial Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,389 0 owned after | $37.64 exercise price | 2022-11-03 | |
| 2022-10-21 holding as of filing | Anderson Erik S Officer (Div. Pres., Breast & Skeletal) | 3 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | Holding | $40.85 exercise price | 2022-10-21 | ||
| 2022-10-21 holding as of filing | Anderson Erik S Officer (Div. Pres., Breast & Skeletal) | 3 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | Holding | $40.97 exercise price | 2022-10-21 | ||
| 2022-10-21 holding as of filing | Anderson Erik S Officer (Div. Pres., Breast & Skeletal) | 3 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | Holding | $47.12 exercise price | 2022-10-21 | ||
| 2022-10-21 holding as of filing | Anderson Erik S Officer (Div. Pres., Breast & Skeletal) | 3 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | Holding | $68.35 exercise price | 2022-10-21 | ||
| 2022-10-21 holding as of filing | Anderson Erik S Officer (Div. Pres., Breast & Skeletal) | 3 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | Holding | $71.13 exercise price | 2022-10-21 | ||
| 2022-10-21 holding as of filing | Mitchell Essex D Officer (Div. President, GYN Surgical) | 3 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | Holding | $40.97 exercise price | 2022-10-21 | ||
| 2022-10-21 holding as of filing | Mitchell Essex D Officer (Div. President, GYN Surgical) | 3 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | Holding | $45.61 exercise price | 2022-10-21 | ||
| 2022-10-21 holding as of filing | Mitchell Essex D Officer (Div. President, GYN Surgical) | 3 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | Holding | $68.35 exercise price | 2022-10-21 | ||
| 2022-10-21 holding as of filing | Mitchell Essex D Officer (Div. President, GYN Surgical) | 3 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | Holding | $71.13 exercise price | 2022-10-21 | ||
| 2022-05-17 | COHN BENJAMIN JORDAN Officer (Principal Accounting Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,844 0 owned after | $40.85 exercise price | 2022-05-19 | |
| 2022-05-13 | COHN BENJAMIN JORDAN Officer (Principal Accounting Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,210 0 owned after | $37.64 exercise price | 2022-05-17 | |
| 2022-05-13 | COHN BENJAMIN JORDAN Officer (Principal Accounting Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,842 3,844 owned after | $40.85 exercise price | 2022-05-17 | |
| 2022-03-10 | Wendell Amy McBride Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,293 5,293 owned after | $70.28 exercise price | 2022-03-14 | |
| 2022-03-10 | Stamoulis Christiana Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,293 5,293 owned after | $70.28 exercise price | 2022-03-14 | |
| 2022-03-10 | Nawana Namal Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,293 5,293 owned after | $70.28 exercise price | 2022-03-14 | |
| 2022-03-10 | Dockendorff Charles J Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,293 5,293 owned after | $70.28 exercise price | 2022-03-14 | |
| 2022-03-10 | HANTSON LUDWIG Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,293 5,293 owned after | $70.28 exercise price | 2022-03-14 | |
| 2022-03-10 | GARRETT SCOTT T Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,293 5,293 owned after | $70.28 exercise price | 2022-03-14 | |
| 2022-03-10 | CRAWFORD SALLY Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,293 5,293 owned after | $70.28 exercise price | 2022-03-14 |